Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsFRA:LDZA -4.07%72 EV-to-OCF is 14.96 as of Sep. 12, 2026, which is 9% below its 10-year median of 16.53. GuruFocus rates FRA:LDZA with a GF Score™ of 72/100 and a GF Value™ of €8.81 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 58.75% on this metric.
The historical rank and industry rank for Aspen Pharmacare Holdings's EV-to-OCF or its related term are showing as below:
FRA:LDZA'
s EV-to-OCF Range Over the Past 10 Years
Min: 10.1 Med: 16.53 Max: 56.21
Current: 14
During the past 13 years, the highest EV-to-OCF of Aspen Pharmacare Holdings was 56.21. The lowest was 10.10. And the median was 16.53.
FRA:LDZA's EV-to-OCF is ranked worse than 58.75% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.305
vs FRA:LDZA: 14.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspen Pharmacare Holdings's PE Ratio (TTM) for today is calculated as:
Aspen Pharmacare Holdings's share price for today is €8.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.212.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aspen Pharmacare Holdings EV-to-OCF Related Terms
Aspen Pharmacare Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's EV-to-OCF falls into.
Aspen Pharmacare Holdings's current Enterprise Value is €5,156 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (FRA:LDZA) has a EV-to-OCF of 14.96 as of Sep. 12, 2026. This is near median its historical median of 16.53. Over the past decade, Aspen Pharmacare Holdings' EV-to-OCF has ranged from 10.10 to 56.21. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #591 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is Aspen Pharmacare Holdings' EV-to-OCF too high?
Aspen Pharmacare Holdings' current EV-to-OCF of 14.96 is near median its 10-year median of 16.53. Over the past 10 years, this metric has ranged from a low of 10.10 to a high of 56.21. The Drug Manufacturers industry median EV-to-OCF is 10.31. Aspen Pharmacare Holdings' value of 14.96 is 45.2% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #591 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #591 out of 1006 companies for EV-to-OCF. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median EV-to-OCF is 10.31. Aspen Pharmacare Holdings' value of 14.96 is 45.2% above this benchmark. Historically, Aspen Pharmacare Holdings' own EV-to-OCF has ranged from 10.10 to 56.21 over the past decade. While the company's 10-year median is 16.53 vs. the industry median of 10.31, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.31, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current EV-to-OCF of 14.96 is 45.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current EV-to-OCF is 14.96, which is near median its own 10-year median of 16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (FRA:LDZA) is currently considered Fairly Valued. The stock's GF Value™ is €8.81, compared to a current price of €8.25 — trading 6.4% below its estimated fair value. The current EV-to-OCF is 14.96, which is near median its 10-year median of 16.53 and 45.2% above the Drug Manufacturers industry median of 10.31. Aspen Pharmacare Holdings' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aspen Pharmacare Holdings (FRA:LDZA), the current EV-to-OCF is 14.96 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (FRA:LDZA) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of €8.25 is trading 6.4% below its estimated GF Value™ of €8.81.
GuruFocus considers Aspen Pharmacare Holdings to be Fairly Valued.
Key valuation signals for FRA:LDZA:
EV-to-OCF: 14.96 (near median its 10-year median of 16.53)
GF Value™: €8.81 vs. price of €8.25 (6.4% below fair value)
Industry Position: 45.2% above the Drug Manufacturers median (#591 of 1006)
No single metric tells the full story. See the FRA:LDZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
72GF Score
Get the complete analysis for FRA:LDZA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDZA has been successfully added to your 
